assertion

Full identifier: http://purl.org/np/RA3-5n-wsBtW7Cs6aHHM0w45zn-KkpfyGGx8nDhJONYFU#assertion

Minted in Nanopublication

 RA3-5n-wsB comment approve/disapprove edit as derived nanopublication

This is a local identifier minted within the nanopublication. http://purl.org/np/RA3-5n-wsB...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RA3-5n-wsB... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA3-5n-wsB...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
assertion
Elif Ozkan
2022-10-13T13:48:59.639Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
assertion
2022-10-13T13:48:59.639916
Elif Ozkan
2022-10-13T13:48:59.639Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
assertion
Avacopan is indicated for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis) in combination with standard therapy including glucocorticoids. In Europe, it is approved for the. treatment of adults with severe, active granulomatic polyang.itis (GPA/MPA) in. combination with rituximab or cyclophosphamide.
Elif Ozkan
2022-10-13T13:48:59.639Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)